FDA Grants Priority Review to Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

The FDA has granted priority review to the supplemental biologics license application seeking the conversion of the accelerated approval of mirvetuximab soravtansine-gynx in patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who previously received 1 to 3 lines of systemic treatment to full approval.

Related Keywords

China ,Michael Vasconcelles ,European Medicines Agency Acceptance ,China National Medical Products Administration ,P European Medicines Agency ,Immunogen Inc ,Prescription Drug User Fee Act ,National Medical Products ,Mirvetuximab Soravtansine ,Elahare ,Ovarian Cancer ,Platinum Resistant Ovarian Cancer ,Frα Platinum Resistant Ovarian Cancer ,Fda ,Priority Review ,Phase 3 Soraya Trial ,Phase 3 Marisol Trial ,Asco Annual Meeting ,Antibody Drug Conjugate ,Sadc ,